May 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wednesday and Thursday, May 19 - 20, 2021. The links can also be found at www.sidoticonference.com/events.

Group Presentation Schedule (click on the company name to register & watch) | ||||
Wednesday, May 19th, 2021 (Day 1) | ||||
*All Times EDT | ||||
8:30-9:00 | **** | |||
9:15-9:45 | ||||
10:00-10:30 | ||||
10:45-11:15 | ||||
11:30-12:00 | **** | |||
12:15-12:45 | ||||
1:00-1:30 | ||||
1:45-2:15 | ||||
2:30-3:00 | ||||
3:15-3:45 | **** | |||
4:00-4:30 | ||||
Thursday, May 20th, 2021 (Day 2) | ||||
*All Times EDT | ||||
8:30-9:00 | **** | |||
9:15-9:45 | **** | |||
10:00-10:30 | **** | |||
10:45-11:15 | ||||
11:30-12:00 | ||||
12:15-12:45 | ||||
1x1s Only - No Presentation | Blueknight (BKEP) || LSB Industries (LXU) | |||
About Sidoti
For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $4 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a small and microcap focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve 500+ institutional clients in North America, including many leading managers of portfolios with $200 million to $2 billion of AUM. Sidoti promotes meaningful interaction between issuers and investors in the small and microcap space through our conferences (www.sidoticonference.com) and the hundreds of non-deal roadshows we host each year.
Contact
Sidoti Events Team
212-453-7031
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | C$2.78 |
| Daily Change: | 0.11 4.12 |
| Daily Volume: | 79,613 |
| Market Cap: | C$90.130M |
November 12, 2025 August 12, 2025 April 07, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load